(Length of Presentation: 23 min)

The first presentation of a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC), called SPARTAN is provided here.  Eric Small presents the SPARTAN trial first data analysis including the background, methods, primary end points, time to metastasis, progression-free survival, time to symptomatic progression, and overall survival.  He concludes with adverse events, and treatment associated adverse events before detailing the findings from the study which were much anticipated in the field of nmCRPC.  Here we see and hear the data that provides the basis for earlier treatment of patients with non-metastatic (M0) CRPC.  

Biographies: Eric J. Small, MD Professor of Medicine; Urology; and Chief, Department of Medicine/Division of Hematology/Oncology, UCSF
Deputy Director; Program Leader, Prostate Cancer Program, UCSF Helen Diller Family Comprehensive Cancer Center
Doris and Donald Fisher Distinguished Professorship in Clinical Cancer Research; Stanford W. Ascherman and Norman R. Ascherman Endowed Chair, UCSF

Read More:

Watch: Changing the Landscape of nmCRPC - The SPARTAN Trial - Eric Small

First Presentation - SPARTAN: A Study of Apalutamide (ARN-509) in Men with Non-Metastatic Castration-resistant Prostate Cancer

Review of First Presentation: SPARTAN and PROSPER

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer